Price
Target price
€0.38
€0.38
2.150%
0.008
2.150%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Thiogenesis Therapeutics Corp.
sharewise wants to provide you with the best news and tools for Thiogenesis Therapeutics Corp., so we directly link to the best financial data sources.
Financials
News
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
Trial achieved biological proof-of-concept, dose discovery and biomarker improvement
San Diego, California, November 4, 2025 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
San Diego, CA, June 25, 2025 – Thiogenesis Therapeutics, Inc. (TSXV: TTI | OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
San Diego, California, June 17, 2025 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”) a clinical-stage biopharmaceutical company developing